Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response

European Journal of Heart Failure

Volumn 17, Issue 9, 2015, Pages 925-935

  Kao, David P ^a   Lewsey, James D ^b   Anand, Inder S ^c   Massie, Barry M ^d   Zile, Michael R ^e   Carson, Peter E ^f   McKelvie, Robert S ^g   Komajda, Michel ^a,h   McMurray, John JV ^b   Lindenfeld, JoAnn ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

^g MCMASTER UNIVERSITY   (Canada)

^h SORBONNE UNIVERSITÉ   (France)

Author keywords

Angiotensin receptor blocker; Candesartan; Heart failure with preserved ejection fraction; Irbesartan; Latent class analysis; Outcomes; Phenotyping

Indexed keywords

CANDESARTAN; IRBESARTAN; PLACEBO; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; AGED; AGING; ANEMIA; ARTICLE; ATRIAL FIBRILLATION; BODY MASS; CLINICAL FEATURE; DIABETES MELLITUS; EVENT FREE SURVIVAL; FEMALE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; KIDNEY FAILURE; LATENT CLASS ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SEX RATIO; STATISTICAL ANALYSIS; TREATMENT RESPONSE; VALIDATION STUDY; VALVULAR HEART DISEASE; VERY ELDERLY; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; EPIDEMIOLOGY; FOLLOW UP; HEART FAILURE; HEART STROKE VOLUME; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TRENDS; UNITED KINGDOM; UNITED STATES;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIPHENYL COMPOUNDS; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; STROKE VOLUME; SURVIVAL RATE; TETRAZOLES; UNITED KINGDOM; UNITED STATES;

EID: 84941808372     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.327     Document Type: Article

References (31)

1. Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray JJ,. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol 2012; 60: 2349-2356.
2. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467.
3. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781.
4. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM,. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011; 4: 27-35.
5. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, Carson PE,. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-331.
6. Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE,. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 2011; 4: 569-577.
7. De Keulenaer GW, Brutsaert DL,. Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation 2011; 123: 1996-2004.
8. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A,. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012; 59: 998-1005.
9. Paulus WJ, Tschöpe C,. A Novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263-271.
10. Lam CS, Brutsaert DL,. Endothelial dysfunction: a pathophysiologic factor in heart failure with preserved ejection fraction. J Am Coll Cardiol 2012; 60: 1787-1789.
11. Lindman BR, Dávila-Román VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, de Las Fuentes L, Joseph SM, Vader J, Hernandez AF, Redfield MM,. Cardiovascular Phenotype in HFpEF Patients With or Without Diabetes: A RELAX Trial Ancillary Study. J Am Coll Cardiol 2014; 64: 541-549.
12. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-2345.
13. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G,. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-1239.
14. Rindskopf D., The use of latent class analysis in medical diagnosis. Proceedings of the Survey Research Methods Section 2002; 2912-6. http://www.amstat.org/sections/srms/Proceedings/y2002/files/JSM2002-000332.pdf (7 Jun 2011)
15. Kim J, Jacobs DR, Luepker RV, Shahar E, Margolis KL, Becker MP,. Prognostic value of a novel classification scheme for heart failure: the Minnesota Heart Failure Criteria. Am J Epidemiol 2006; 164: 184-193.
16. Lanza ST, Rhoades BL,. Latent class analysis: an alternative perspective on subgroup analysis in prevention and treatment. Prev Sci 2013; 14: 157-168.
17. Kao DP, Wagner BD, Robertson AD, Bristow MR, Lowes BD,. A Personalized BEST: Characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol. PLoS One 2012; 7:e48184.
18. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS,. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011; 13: 18-28.
19. Cheng CP, Cheng HJ, Cunningham C, Shihabi ZK, Sane DC, Wannenburg T, Little WC,. Angiotensin II type 1 receptor blockade prevents alcoholic cardiomyopathy. Circulation 2006; 14: 226-236.
20. Ho JE, Lyass A, Lee DS, Vasan RS, Kannel WB, Larson MG, Levy D,. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail 2012; 6: 279-286.
21. Chambers J., The left ventricle in aortic stenosis: evidence for the use of ACE inhibitors. Heart 2006; 92: 420-423.
22. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
23. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T,. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
24. Linzer D, Jeffrey J,. poLCA: polytomous variable latent class analysis R package version 1.2. 2010; http://dlinzer.github.io/poLCA (27 Jul 2015)
25. White IR, Royston P, Wood AM,. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 2011; 30: 377-399.
26. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang CC, Deo RC,. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 2015; 131: 269-279.
27. Ahmad T, Pencina MJ, Schulte PJ, O'Brien E, Whellan DJ, Piña IL, Kitzman DW, Lee KL, O'Connor CM, Felker GM,. Clinical implications of chronic heart failure phenotypes defined by cluster analysis. J Am Coll Cardiol 2014; 64: 1765-1774.
28. Cook NR,. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928-935.
29. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J,. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3: 283-291.
30. Ono T, Sanai T, Miyahara Y, Noda R,. Olmesartan is more effective than other angiotensin receptor antagonists in reducing proteinuria in patients with chronic kidney disease other than diabetic nephropathy. Curr Ther Res Clin Exp 2013; 74: 62-67.
31. Nakamura T, Fujiwara N, Sato E, Ueda Y, Sugaya T, Koide H,. Renoprotective effects of various angiotensin ii receptor blockers in patients with early-stage diabetic nephropathy. Kidney Blood Press Res 2010; 33: 213-220.